Glucagon-like-peptide-1 (GLP-1) receptor agonists are used for the treatment of type 2 diabetes. These incretin-based therapies are a group of injectable medicines, but they are now used routinely for the treatment of type 2 diabetes.
Lyxumia is a once-daily GLP-1 receptor agonist. It is administered via an easy-to-use fixed dose pen device.
To help your patients to administer their Lyxumia safely in an informed manner, Sanofi have developed a range of patient support materials. If you would like to see a Sanofi representative in person to discuss Lyxumia please click on the button below.
- View the Lyxumia prescribing information here
- View the Lyxumia summary of product characteristics here